Abstract
Alzheimer’s Disease (AD), the most common neurodegenerative disorder, presents a significant challenge for early detection and intervention due to its complex etiology involving genetic, environmental, and lifestyle factors. This study harnesses the innovative potential of artificial intelligence (AI) through the aiHumanoid platform to simulate AD progression. In this study, we focus on the impact of two APOE genotypes on disease development and progression. Our longitudinal virtual subject simulations, grounded in extensive medical literature and genetic information, explore the nuanced interplay between specific genetic variants, APOE ε3/4 and ε4/4, and their role in AD’s heterogeneity. Despite the potential limitations associated with emerging technologies, including the translatability of AI simulations to real-world scenarios and the scope of genetic variants, this research provides key insights into early biomarkers and the progression patterns of AD. Future segments of this study (Part 2 and Part 3) will broaden the analysis to encompass a wider array of genetic factors and their interactions, enhancing the understanding of AD and paving the way for personalized intervention strategies. Ethical considerations surrounding the use of AI in medical research are acknowledged, emphasizing the need for responsible integration of technology in healthcare. Our findings underscore the transformative potential of AI in advancing AD research, offering a foundation for future studies aimed at refining diagnostic and therapeutic approaches through enhanced realism in simulations and a comprehensive exploration of genetic and environmental factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
